UTHR|Analyst Targets
UTHR|Company Info
UTHR|Insider Trading
UTHR|Fundamentals
UTHR|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $6.82 | - | - |
| Q3'26 | $6.55 | $5.71 | -12.9% |
| Q2'26 | $6.86 | $7.27 | +5.9% |
| Q4'25 | $7.33 | $7.70 | +5.1% |
| Q4'24 | $6.27 | $6.19 | -1.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $883M | - | - |
| Q3'26 | $797M | $833M | +4.5% |
| Q2'26 | $822M | $783M | -4.7% |
| Q4'25 | $829M | $790M | -4.7% |
| Q4'24 | - | $736M | - |
UTHR|Monthly Returns
Market Data
UTHR Stock Snapshot
- Market cap
- 23.00B
- P/E ratio
- 18.7
- Day range
- $550.23 – $563.12
- News sentiment
- 57/100 · Neutral
- Analyst target
- $687.14 (+23.9%)
- Consensus
- Buy · 23 analysts
Trend, momentum and range position line up bullish on UTHR at the moment. Earnings and guidance carry more weight than macro data at this capitalisation.
Behaviour On Record
What UTHR's own history says about today's numbers
- Realized volatility (21d)
- 32.5% 59th pct
- Below its peak
- -8.8%
- vs 200-day average
- +2.8%
- Up days (1y)
- 47%
United Therapeutics Corporation is currently running 32.5% annualised volatility over the last 21 sessions. Measured against UTHR's own 13 years of daily returns rather than a market-wide average, that is the 59th percentile — close to its own typical level, against a typical reading of 30.1%.
UTHR is trading -8.8% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -27.8%, and the deepest was -41.1% in 2019. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +2.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 49th percentile — close to the gap it normally carries. Over the past year UTHR closed higher on 47% of sessions, and it is currently 7 sessions into a falling streak.
On November specifically: over 13 years of records, UTHR finished the month higher 8 of 13 times, with a median return of +2.6% and an average of +3.8%. Its strongest month historically has been October at +5.2% on average, its weakest September at -1.8%.
Overnight risk is measurable too: UTHR has opened more than 2% away from the prior close in 121 of 3,267 sessions (3.7% of the time), with the largest gaps running +51.0% and -12.9%.
Across the last 3 dated reports on file, UTHR moved an average of 5.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -5.9% and a largest of -7.0%.
All figures computed from 3,268 daily closes between 2013-11-22 and 2026-11-20, split-adjusted, recomputed daily. Percentiles are against UTHR's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of UTHR's sector?
United Therapeutics Corporation sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #5 of 12
- Sector state
- Leading
- Sector rotation score
- 82
Analyst Rating Changes
Are analysts turning bullish or bearish on UTHR?
TD Cowen most recently reiterated its rating on United Therapeutics Corporation to Buy on Nov 5, 2026 with a price target of $700 (from $675). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- TD Cowen: Buy
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
Earnings Release, Scored
What did United Therapeutics Corporation's latest earnings release say?
Most important lines
- 1
of therapies and their potential to exponentially increase the number of patients that we can serve; new opportunities across cardiopulmonary and respiratory medicine; the timing of the final settlement of the September 2026 ASR; the timing, structure and use of our share repurchase program; and our goals of innovating for the unmet medical needs of our patients and to benefit our other stakeholders, furthering our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.
New this quarter - 2
Our ETR for the three months ended September 30, 2026 increased compared to our ETR for the three months ended September 30, 2025, primarily due to nondeductible IPR&D expense related to the acquisition of Thymmune, which was capitalized for tax purposes into the basis of the stock acquired.
New this quarter - 3
Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025.
Peers & ETF holders
UTHR peers & ETF holders
Drug Manufacturers - Specialty & GenericMarket cap · today
- UTHRYou're here$23.0B0.00%
- ZTSZoetis Inc.$32.0B-1.19%
- VTRSViatris Inc.$22.0B-0.10%
News & sentiment
What is the news saying about UTHR?
UTHR fell 0.8% over the month to Nov 20. News tone held between 33 and 73 from Oct 20 to Nov 16, then jumped to 68 on Nov 17.
- Oct 22 +3.8%same day: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
- Nov 5 -7.0%same day: What Is Drawing Attention To United Therapeutics (UTHR) Today?
- Nov 9 +3.6%same day: United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
Technical analysis
How strong is UTHR's momentum right now?
On the daily chart UTHR ranks at the 71st percentile for momentum against 1,063 stocks and ETFs, a bullish reading.
Institutional ownership
Are big funds buying or selling UTHR?
95 of the 195 tracked managers added to UTHR in their latest 13F and 93 trimmed. Together they own 77.1% of the company, worth $17.3B. BlackRock and State Street alone hold 18.2%.
- 1BlackRock, Inc.13.45%$3.0B positionAdded 5.3% last quarter
- 2State Street Corp4.71%$1.1B positionAdded 2.9% last quarter
- $1.0B positionAdded 0.6% last quarter
- $1.0B positionTrimmed 0.4% last quarter
- $1.0B positionAdded 37.7% last quarter
- $908.2M positionTrimmed 1.9% last quarter
- 7Amundi2.38%$535.8M positionAdded 351.3% last quarter
- $527.2M positionTrimmed 2.2% last quarter
- 9Citadel Advisors LLC2.24%$503.1M positionAdded 204.7% last quarter
- 10Invesco Ltd.1.94%$436.9M positionAdded 70.4% last quarter
Congressional trading
Is Congress trading UTHR?
1 member of Congress disclosed 3 UTHR trades between Oct 30 and Oct 31, 2025: 1 buy and 2 sells, about $24.0K in estimated value.
What stands out
Click one to highlight its trades in the chartDiscover more
How has UTHR done against its peers?
Over the six months to Nov 20, UTHR returned −1.6%. Of the 15 related stocks and ETFs, 14 did better, led by MRNA at +304.6%.
- 1MRNAModerna, Inc.up 304.6%+306.2 pts
- 2REGNRegeneron Pharmaceuticals, Inc.up 42.5%+44.2 pts
- 3BIIBBiogen Inc.up 33.5%+35.2 pts
- 4INSMInsmed Incorporatedup 32.6%+34.3 pts
- 5AMGNAmgen Inc.up 31.7%+33.3 pts
- 6RPRXRoyalty Pharma plcup 29.4%+31.0 pts
- 7ARKGARK Genomic Revolution ETFup 29.3%+31.0 pts
- 8GILDGilead Sciences, Inc.up 27.9%+29.6 pts
- 15UTHRThis stockdown 1.6%
- 16ALNYAlnylam Pharmaceuticals, Inc.down 51.5%−49.8 pts